Ⓐ
PeptiBrief
Evidence Library
pooled_randomized_phase_3_trials · 2010

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation

Falutz J|et al. · Journal of Clinical Endocrinology and Metabolism
highPMID · 20554713Verified
View source
Plain-English summary

Tesamorelin reduced visceral abdominal fat in the studied HIV-associated lipodystrophy population.

Population
Adults with HIV and excess abdominal fat
Intervention
Tesamorelin versus placebo
Outcomes measured
Visceral adipose tissue|body composition|safety
Key findings
Clinically meaningful visceral-fat reduction in the licensed population.
Limitations
Results are indication-specific and should not be generalized to routine obesity treatment.
Risk of bias
Moderate due to sponsor involvement despite randomized controlled design.
Citation
Falutz J|et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation. Journal of Clinical Endocrinology and Metabolism
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.